Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?

Archives of Internal Medicine

Volumn 160, Issue 5, 2000, Pages 685-693

  Bakris, George L ^a   Weir, Matthew R ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RAMIPRIL;

ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; META ANALYSIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CREATININE; DECISION TREES; DIABETES COMPLICATIONS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; HYPERKALEMIA; KIDNEY FAILURE; MULTICENTER STUDIES; POTASSIUM; RANDOMIZED CONTROLLED TRIALS; RISK; RISK FACTORS;

EID: 0034642827     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
2. Taylor Nelson Healthcare, Epson Survey. London, England: Copyright Cardiomonitor; 1992.
3. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al, for the MDRD Group. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension. 1997; 29:641-650.
4. Weir MR, Chrysant SG, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension. 1998; 31:1088-1096.
5. Ball SG, Hall AS, Murray GD. ACE inhibition, atherosclerosis and myocardial infarction - the AIRE Study in practice: Acute Infarction Ramipril Efficacy Study. Eur Heart J. 1994;15(suppl B):20-25.
6. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327: 669-677.
7. Gustafsson F, Kober L, Torp-Pedersen C, et al. Long-term prognosis after acute myocardial infarction in patients with a history of arterial hypertension: TRACE study group. Eur Heart J. 1998;19:588-594.
8. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy: results of a six year study. Kidney Int. 1996;50:1641-1650.
9. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Disease trial. N Engl J Med. 1996;334:939-945.
10. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
11. Hebert LA, Bain RP, Verne D, for the Collaborative Study Group. Remission of nephrotic range proteinuria in type I diabetes. Kidney Int. 1994;46:1688-1693.
12. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-corverting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
13. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int. 1994;45(suppl 45):S-150-S-155.
14. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ. 1994;309:833-837.
15. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
16. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ. 1992;304:339-343.
17. Zucchelli P, Zuccala A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992;42:452-458.
18. Kamper AL, Strandgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. Am J Hypertens. 1992;5:423-430.
19. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in non-diabetic progressive renal insufficiency: a controlled double-blinded trial. Am J Kidney Dis. 1996;27:489-495.
20. Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitor. Ann Pharmacother. 1996;30:55-61.
21. Toto RD. Renal insufficiency due to angiotensin-converting enzyme inhibitors. Miner Electrolyte Metab. 1994;20:193-200.
22. Anderson S, Rennke HG, Brenner BM. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int. 1992;41:891-897.
23. Christensen PK, Hansen HP, Parving HH. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int. 1997;52:1369-1374.
24. Bidani AK, Griffin KA, Plott W, Schwartz MM. Renal ablation acutely transforms "benign" hypertension to "malignant" nephrosclerosis in hypertensive rats. Hypertension. 1994;24:309-316.
25. Levey A. Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996;7:2097-2109.
26. Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving HH. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int. 1995;47:1726-1731.
27. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group [published erratum appears in N Engl J Med. 1994;330:152]. N Engl J Med. 1993; 329:1456-1462.
28. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1994;43:1108-1113.
29. Bakris GL. Short- and long-term effects of ACE inhibitors on progression of renal disease. Nephrology. 1997;3(suppl 1):S40.
30. Keane WF, Eknoyan G, for the PARADE Committee. Proteinuria, albuminuria, risk assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis. 1999;33:1004-1010.
31. Remuzzi G, Ruggenenti P, Benigni A, Understanding the nature of renal disease progression. Kidney Int. 1997;51:2-15.
32. Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int. 1998;53:1559-1573.
33. Locatelli F, Carbarns IR, Maschio G, et al. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study: the Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney Int. 1997; 63:S63-S66.
34. Ruggenenti P, Perna A, Benini R, Remuzzi G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathy. J Am Soc Nephrol. 1998;9: 2096-2101.
35. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med. 1998;158:26-32.
36. Rodby RA, Rohde R, Evans J, Bain RP, Mulcahy WS, Lewis EJ. The study of the effect of intensity of blood pressure management on the progression of type I diabetic nephropathy: study design and baseline patient characteristics, Collaborative Study Group. J Am Soc Nephrol. 1995;5:1775-1781.
37. Gansevoort RT, deZeeuw D, Shahinfar S, Redfield A, de Jong PE. Etfects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens. 1994;12(suppl 2):S-37-S-42.
38. Bakris GL, Siomos M, Kasprowicz S, et al. Differential effects of ACE inhibitors and angiotensin-1 receptor blockers on potassium homeostasis in nephropathy [abstract]. Am J Hypertens. 1999;12:36A.
39. Brown SA, Brown CA. Single-nephron adaptations to partial renal ablation in cats. Am J Physiol. 1995;269(5 pt 2):R1002-R1008.
40. Yoshioka T, Shiraga H, Yoshida Y, et al. "Intact nephrons" as the primary origin of proteinuria in chronic renal disease: study in the rat model of subtotal nephrectomy. J Clin Invest. 1988;82:1614-1623.
41. Tarif N, Bakris GL. Angiotensin II receptor blockade and progression of renal disease in nondiabetic patients. Kidney Int. 1997;52(suppl 63):S-67-S-70.
42. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic man: importance of therapeutic selection. Kidney.Int. 1992;41:912-919.
43. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest. 1995;96:793-800.
44. Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999;55: 1849-1860.
45. Tietze IN, Sorensen SS, Ivarsen PR, Nielsen CB, Pedersen EB. Impaired renal hemodynamic response to amino acid infusion in essential hypertension during angiotensin converting enzyme inhibitor treatment. J Hypertens. 1997;15:551-560.
46. Herrera J, Rodriguez-Iturbe B. Stimulation of tubular secretion of creatinine in health and in conditions associated with reduced nephron mass: evidence for a tubular functional reserve. Nephrol Dial Transplant. 1998;13:623-629.
47. Bohler J, Woitas R, Keller E, Reetze-Bonorden P, Schollmeyer PJ. Effect of nifedipine and captopril on glomerular hyperfiltration in normotensive man. Am J Kidney Dis. 1992;20:132-139.
48. Jaffa AA, Vio CP, Silva RH, et al. Evidence for renal kinins as mediators of amino acid-induced hyperperfusion and hyperfiltration in the rat. J Clin Invest. 1992; 89:1460-1468.
49. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? a systematic review. JAMA. 1998; 279:1903-1907.
50. Garber L, Walton C, Brown S, Bakris G. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int. 1994;46:161-169.
51. Rabelink TJ, Bakris GL. The renin-angiotensin system in diabetic nephropathy: the endothelial connection. Miner Electrolyte Metab. 1998;24:381-388.
52. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation. 1996;94:258-265.
53. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavia Enalapril Survival Study. N Engl Med J. 1987;316:1429-1435.